S. 5059: To amend the Public Health Service Act to streamline the review of biosimilar biological products.

This bill would make a narrow change to the federal law that governs biosimilar biological products—products that are designed to be highly similar to an already-approved biological drug, often used as lower-cost alternatives to brand-name biologic medicines.

What it changes

The bill amends one specific part of the Public Health Service Act that deals with the review process for biosimilars. In practical terms, it would:

• remove one existing subparagraph from that section of the law;

• renumber a later subparagraph to take its place.

Likely practical effect

Because the bill only changes the wording and structure of one subsection, it appears intended to streamline or simplify the legal framework for reviewing biosimilar products. The bill text itself does not spell out a detailed new approval standard, timeline, or agency procedure, so the exact operational effect would depend on how the rest of the statute and FDA review process apply after the change.

What it does not do

Based on the text provided, the bill does not appear to:

• change the basic definition of a biosimilar;

• set new pricing rules;

• create a new program or agency;

• directly approve any specific drug;

• make broader changes to prescription drug regulation beyond this one review provision.

Relevant Companies

None found